Proactive Investors - Run By Investors For Investors

Feedback advancing clinical use of TexRAD after bagging CE mark

Alastair Riddell, chairman of Feedback plc (LON:FDBK) tells Proactive they're now able to crack on with expanding the clinical use of  TexRAD in the treatment of lung cancer across the EU after finally receiving a CE mark for the technology earlier this week.

The award of the CE mark means Feedback can now sell TexRAD Lung to hospitals, satisfying the quality, safety and performance standards required for medical devices in the European Union.

This particular version of the product will help doctors diagnose and treat people with lung cancer, the most common and most deadly form of the disease.

 
Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full FDBK profile View Profile

Feedback PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use